surmount-1 tirzepatide non-diabetic obesity weight loss GLP-1 Agonists For In Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH SURMOUNT-1 Trial - Cardionerds Twitter

V.VishwanathB

January 2026 is aligning with commonly observed early-year interest in oral GLP-1 peptide options, as consumers compare different administration formats during seasonal "new year, new you" wellness behavior

It exists because your GLP-1 receptors need time to adjust to the medication

Yes, combining the medication with a reduced-calorie diet and regular exercise enhances weight loss results and supports long-term success

2025 Oct 7;122(40):e2502841122

Zydus Lifesciences' SEMAGLYN, MASHEMA and ALTERME Zydus Lifesciences has also entered the segment with its semaglutide offering, using a reusable multi-dose pen device